Literature DB >> 2879266

Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia.

R P Simon, R S Young, S Stout, J Cheng.   

Abstract

Excitatory amino acid neurotransmitters have been implicated in fostering brain edema and neuronal death in ischemia. As both of these processes are involved in nervous system damage during neonatal anoxia, the effect of blockade of cell excitation with kynurenate upon brain water was studied following anoxic-ischemic brain injury in neonatal rats. Such treatment attenuated brain edema immediately after, and 24 h following anoxia-ischemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2879266     DOI: 10.1016/0304-3940(86)90648-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

Review 1.  Kynurenines and intestinal neurotransmission: the role of N-methyl-D-aspartate receptors.

Authors:  József Kaszaki; Dániel Erces; Gabriella Varga; Andrea Szabó; László Vécsei; Mihály Boros
Journal:  J Neural Transm (Vienna)       Date:  2011-05-27       Impact factor: 3.575

2.  Kynurenic acid attenuates multiorgan dysfunction in rats after heatstroke.

Authors:  Yi-chang Hsieh; Ruei-feng Chen; Yi-shian Yeh; Mao-tsun Lin; Jui-hsiang Hsieh; Sheng-hsien Chen
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

3.  Pretreatment with a competitive NMDA antagonist D-CPPene attenuates focal cerebral infarction and brain swelling in awake rats.

Authors:  C K Park; J McCulloch; J K Kang; C R Choi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  The Kynurenic Acid Analog SZR72 Enhances Neuronal Activity after Asphyxia but Is Not Neuroprotective in a Translational Model of Neonatal Hypoxic Ischemic Encephalopathy.

Authors:  Viktória Kovács; Gábor Remzső; Tímea Körmöczi; Róbert Berkecz; Valéria Tóth-Szűki; Andrea Pénzes; László Vécsei; Ferenc Domoki
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

5.  Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Dalia Abou-Kassem; Anna Koldbro Hansted; Kumari Ubhayasekera; Jonas Bergquist; László Vécsei; Inger Jansen-Olesen; Messoud Ashina
Journal:  Pharmacol Res Perspect       Date:  2021-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.